Changes in adiponectin level and fat distribution in patients with type 2 diabetes

European Journal of Clinical Investigation

Volumn 44, Issue 2, 2014, Pages 192-199

  Miazgowski, Tomasz ^a   Dziwura Ogonowska, Joanna ^a   Safranow, Krzysztof ^a   Iskierska, Katarzyna ^a   Widecka, Krystyna ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Abdominal fat; Adiponectin; Body fat; Hip fat; Metabolic syndrome

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL FAT; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIFESTYLE MODIFICATION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; WEIGHT REDUCTION; ADIPOSE TISSUE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET; METABOLIC SYNDROME X; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADIPOSE TISSUE; AGED; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; WAIST CIRCUMFERENCE;

EID: 84892487330     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12207     Document Type: Article

References (38)

1. Yoshimura E, Kumahara H, Tobina T, Matono S, Kiyanaga A, Kimura M et al. Relationships between fat deposition in the liver and skeletal muscle and insulin sensitivity in Japanese individuals: a pilot study. Diabetes Metab Syndr Obes 2011;4:35-43.
2. Zhang H, Chen X, Sairam MR. Novel hormone-regulated genes in visceral adipose tissue: cloning and identification of proinflammatory cytokine-like mouse and human MEDA-7: implications for obesity, insulin resistance and the metabolic syndrome. Diabetologia 2011;54:2368-80.
3. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest 2011;121:2094-101.
4. Zhuo Q, Wang ZQ, Fu P, Piao JH, Tian Y, Hu J et al. Association between adiponectin and metabolic syndrome in older adults from major cities of China. Biomed Environ Sci 2010;23:53-61.
5. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:446-52.
6. Cook JR, Semple RK. Hypoadiponectinemia - cause or consequence of human "Insulin Resistance"? J Clin Endocrinol Metab 2010;95:1544-54.
7. Brooks NL, Moore KS, Clark RD, Perfetti MT, Trent CM, Coombs TP et al. Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome? Diabetes Obes Metab 2007;9:246-58.
8. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO; 1999.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):62-9.
10. American Diabetes Association. Standards of medical care - 2010. Diabetes Care 2010;33(Suppl 1):11-61.
11. Lee K, Lee S, Kim YJ, Kim YJ. Waist circumference, dual-energy X-ray absortiometrically measured abdominal adiposity, and computed tomographically derived intra-abdominal fat area on detecting metabolic risk factors in obese women. Nutrition 2008;24:625-31.
12. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
13. Atp III. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
14. Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006;65:722-8.
15. Harris MI, Klein TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-19.
16. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 1996;13:337-40.
17. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
18. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312-19.
19. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K et al. Effects of pioglitazone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002;51:314-17.
20. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB et al. Induction of adipocyte complement-related protein of 20 kilo Daltons by PPAR gamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007.
21. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
22. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-76.
23. Araki T, Emoto M, Konishi T, Ikuno Y, Lee E, Teramura M et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism 2009;58:143-8.
24. Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003;26:285-9.
25. Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T et al. Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2005;328:484-90.
26. Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007;66:282-9.
27. Phillips SA, Kung J, Ciaraldi TP, Choe C, Christiansen L, Mudaliar S et al. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab 2009;297:E767-73.
28. Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T et al. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J 2005;52:427-33.
29. Huypens P, Quartier E, Pipeleers D, Van den Casteele M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 2005;518:90-5.
30. Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 2007;145:52-5.
31. Drzewoski J, Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. Curr Med Res Opin 2006;22:1921-6.
32. Zulian A, Cancello R, Girola A, Gilargini L, Alberti L, Croci M et al. In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obesity Facts 2011;4:27-33.
33. Kanda Y, Matsuda M, Tawaramoto K, Kawasaki F, Hashiramoto M, Matsuki M et al. Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone. Diabetes Res Clin Pract 2008;81:13-18.
34. Owecki M, Miczke A, Pupek-Musialik D, Bryll W, Cymerys M, Nikisch E et al. Serum adiponectin concentrations are not related to glycosylated hemoglobin levels (HbAlc) in obese diabetic and non-diabetic Caucasians. Exp Clin Endocrinol Diabetes 2008;116:173-7.
35. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542-8.
36. Abbasi F, Chang SA, Chu JW, Ciaraldi TP, Lamendola C, McLaughlin T et al. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol 2006;290:139-44.
37. Kang SM, Yoon JW, Ahn HY, Kim SY, Lee KH, Shin H et al. Android fat depot is more closely associated with metabolic syndrome than abdominal visceral fat in elderly people. PLoS ONE 2011;6:e276.
38. Park YW, Heymsfield SB, Gallagher D. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? Int J Obes Relat Metab Disord 2002;26:978-83.